PMC:7264098 / 12096-13684 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"289","span":{"begin":1085,"end":1089},"obj":"Gene"},{"id":"290","span":{"begin":966,"end":974},"obj":"Species"},{"id":"291","span":{"begin":1424,"end":1432},"obj":"Species"},{"id":"292","span":{"begin":1548,"end":1556},"obj":"Species"},{"id":"293","span":{"begin":1111,"end":1122},"obj":"Chemical"},{"id":"294","span":{"begin":183,"end":191},"obj":"Disease"},{"id":"295","span":{"begin":770,"end":778},"obj":"Disease"},{"id":"296","span":{"begin":870,"end":890},"obj":"Disease"},{"id":"297","span":{"begin":979,"end":998},"obj":"Disease"},{"id":"298","span":{"begin":1052,"end":1060},"obj":"Disease"},{"id":"299","span":{"begin":1460,"end":1464},"obj":"Disease"},{"id":"300","span":{"begin":1539,"end":1547},"obj":"Disease"},{"id":"301","span":{"begin":1562,"end":1587},"obj":"Disease"}],"attributes":[{"id":"A289","pred":"tao:has_database_id","subj":"289","obj":"Gene:3569"},{"id":"A290","pred":"tao:has_database_id","subj":"290","obj":"Tax:694009"},{"id":"A291","pred":"tao:has_database_id","subj":"291","obj":"Tax:9606"},{"id":"A292","pred":"tao:has_database_id","subj":"292","obj":"Tax:9606"},{"id":"A293","pred":"tao:has_database_id","subj":"293","obj":"MESH:C502936"},{"id":"A294","pred":"tao:has_database_id","subj":"294","obj":"MESH:C000657245"},{"id":"A295","pred":"tao:has_database_id","subj":"295","obj":"MESH:C000657245"},{"id":"A296","pred":"tao:has_database_id","subj":"296","obj":"MESH:D060085"},{"id":"A297","pred":"tao:has_database_id","subj":"297","obj":"MESH:D018352"},{"id":"A298","pred":"tao:has_database_id","subj":"298","obj":"MESH:C000657245"},{"id":"A299","pred":"tao:has_database_id","subj":"299","obj":"MESH:D012128"},{"id":"A300","pred":"tao:has_database_id","subj":"300","obj":"MESH:C000657245"},{"id":"A301","pred":"tao:has_database_id","subj":"301","obj":"MESH:D012131"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T75","span":{"begin":266,"end":269},"obj":"Body_part"},{"id":"T76","span":{"begin":625,"end":639},"obj":"Body_part"},{"id":"T77","span":{"begin":1101,"end":1109},"obj":"Body_part"},{"id":"T78","span":{"begin":1152,"end":1158},"obj":"Body_part"},{"id":"T79","span":{"begin":1174,"end":1189},"obj":"Body_part"},{"id":"T80","span":{"begin":1365,"end":1369},"obj":"Body_part"},{"id":"T81","span":{"begin":1370,"end":1376},"obj":"Body_part"},{"id":"T82","span":{"begin":1490,"end":1499},"obj":"Body_part"},{"id":"T83","span":{"begin":1495,"end":1499},"obj":"Body_part"}],"attributes":[{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma24890"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A81","pred":"fma_id","subj":"T81","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A82","pred":"fma_id","subj":"T82","obj":"http://purl.org/sig/ont/fma/fma63368"},{"id":"A83","pred":"fma_id","subj":"T83","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T20","span":{"begin":266,"end":269},"obj":"Body_part"},{"id":"T21","span":{"begin":1365,"end":1369},"obj":"Body_part"},{"id":"T22","span":{"begin":1370,"end":1376},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"uberon_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"},{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A22","pred":"uberon_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T87","span":{"begin":183,"end":191},"obj":"Disease"},{"id":"T88","span":{"begin":770,"end":778},"obj":"Disease"},{"id":"T89","span":{"begin":880,"end":890},"obj":"Disease"},{"id":"T90","span":{"begin":955,"end":964},"obj":"Disease"},{"id":"T91","span":{"begin":966,"end":974},"obj":"Disease"},{"id":"T92","span":{"begin":966,"end":970},"obj":"Disease"},{"id":"T93","span":{"begin":988,"end":998},"obj":"Disease"},{"id":"T94","span":{"begin":1052,"end":1060},"obj":"Disease"},{"id":"T95","span":{"begin":1460,"end":1464},"obj":"Disease"},{"id":"T96","span":{"begin":1539,"end":1547},"obj":"Disease"}],"attributes":[{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A90","pred":"mondo_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A92","pred":"mondo_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A93","pred":"mondo_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T122","span":{"begin":19,"end":20},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T123","span":{"begin":266,"end":269},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T124","span":{"begin":545,"end":546},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T125","span":{"begin":1152,"end":1158},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T126","span":{"begin":1365,"end":1369},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T127","span":{"begin":1365,"end":1369},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T128","span":{"begin":1490,"end":1499},"obj":"http://purl.obolibrary.org/obo/CL_0000034"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T39","span":{"begin":353,"end":357},"obj":"Chemical"},{"id":"T40","span":{"begin":447,"end":451},"obj":"Chemical"},{"id":"T41","span":{"begin":586,"end":601},"obj":"Chemical"},{"id":"T42","span":{"begin":712,"end":727},"obj":"Chemical"},{"id":"T43","span":{"begin":1085,"end":1087},"obj":"Chemical"}],"attributes":[{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A44","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T19","span":{"begin":1388,"end":1400},"obj":"http://purl.obolibrary.org/obo/GO_0031099"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T69","span":{"begin":0,"end":192},"obj":"Sentence"},{"id":"T70","span":{"begin":193,"end":460},"obj":"Sentence"},{"id":"T71","span":{"begin":461,"end":696},"obj":"Sentence"},{"id":"T72","span":{"begin":697,"end":1022},"obj":"Sentence"},{"id":"T73","span":{"begin":1023,"end":1311},"obj":"Sentence"},{"id":"T74","span":{"begin":1312,"end":1588},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

2_test

{"project":"2_test","denotations":[{"id":"32574317-32043983-31466311","span":{"begin":1016,"end":1020},"obj":"32043983"},{"id":"32574317-32113510-31466312","span":{"begin":1288,"end":1292},"obj":"32113510"},{"id":"32574317-32290839-31466313","span":{"begin":1305,"end":1309},"obj":"32290839"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

MyTest

{"project":"MyTest","denotations":[{"id":"32574317-32043983-31466311","span":{"begin":1016,"end":1020},"obj":"32043983"},{"id":"32574317-32113510-31466312","span":{"begin":1288,"end":1292},"obj":"32113510"},{"id":"32574317-32290839-31466313","span":{"begin":1305,"end":1309},"obj":"32290839"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19. Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects. Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results. In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020). Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020). Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications."}

PMC:7264098 / 12096-13684 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7264098 / 12096-13684 JSON TXT